Intellia Therapeutics (LTS:0JBU) Interest Income : $50.25 Mil (TTM As of Jun. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Intellia Therapeutics Interest Income?

Interest Income is the interest earned on cash temporarily held in savings accounts, certificates of deposits, or other investments. Intellia Therapeutics's interest income for the three months ended in Jun. 2024 was $12.42 Mil. Its interest income for the trailing twelve months (TTM) ended in Jun. 2024 was $50.25 Mil.

Intellia Therapeutics Interest Income Historical Data

The historical data trend for Intellia Therapeutics's Interest Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intellia Therapeutics Interest Income Chart

Intellia Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Income

Get a 7-Day Free Trial

6.84

2.35

1.28

8.54

49.83

Intellia Therapeutics Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Interest Income	Get a 7-Day Free Trial															12.65	12.74	12.46	12.63	12.42

Intellia Therapeutics Interest Income Calculation

Interest Income is the interest earned on cash temporarily held in savings accounts, certificates of deposits, or other investments.

Interest Income for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $50.25 Mil.

Intellia Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Intellia Therapeutics Inc (LTS:0JBU) » Definitions » Interest Income

Comparable Companies

Traded in Other Exchanges

NTLA:USA 38I:Germany

Address

40 Erie Street, Suite 130, Cambridge, MA, USA, 02139

Website

https://www.intelliatx.com

Intellia Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Intellia Therapeutics Headlines

No Headlines